Zenas BioPharma
ZBIO
28.18
+1.24
+4.60%
Zenas BioPharma
US · ZBIO
#2856 by market cap
Listed 2024
28.18
+1.24
+4.60%
Live - 5344 symbols - heartbeat 510s ago
· 2026-10-08 07:09
Pre-market
28.26
+0.28%
After-hours
28.18
0.00%
- Market cap
- 1.84B
- P/E (TTM)i
- -2.93
- P/Bi
- 7.43
- EPSi
- -8.44
- Div yieldi
- 0.00%
- 52W posi
- 47%
Reader sentiment
Are you bullish or bearish on ZBIO?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership rose 6.5 percentage points.
Institutional ownership
- Held by institutions
- 123.85% +6.52pp
- Institutions
- 184 +1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund62.53%
VC/PE Fund24.22%
Public Company18.22%
Hedge Fund14.71%
Private Company4.02%
Individual/Insider1.52%
Government Pension Fund0.13%
Top holders as of 2026-06-30
FMR
14.59% · 9.51M sh
InnoCare Pharma Limited
10.74% · 7.00M sh
Wellington Management Group
10.07% · 6.57M sh
SR One Capital Management, LP
7.73% · 5.04M sh
New Enterprise Associates, Inc.
6.17% · 4.02M sh
Zebra Aggregator, LP
4.98% · 3.25M sh
Federated Hermes, Inc.
4.78% · 3.12M sh
Xencor, Inc.
4.75% · 3.10M sh
BlackRock
4.12% · 2.69M sh
Longitude Capital Management Co., LLC
4.00% · 2.61M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 49 buys · 0 sells
| Name | Role | Stake |
|---|---|---|
| InnoCare Pharma Limited | -- | 10.74% |
| Wellington Management Group | -- | 10.07% |
| Leon Moulder | Chairperson & CEO | 0.80% |
| Hongbo Lu | Director | 0.65% |
| Patricia L. Allen | Director | 0.03% |
| Patrick Gerald Enright | Director | 0.02% |
| Tim Xiao | Director | 0.02% |
| Joseph Farmer | Chief Operating Officer | 0.00% |
| Jennifer Fox | Chief Business Officer & CFO | 0.00% |
| Jason Nunn | Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-31 | Christy Oliger | Independent Director | Other Derivative Acquisition | +37,000 | $31.98 |
| 2026-08-25 | InnoCare Pharma Limited | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-06-14 | Leon Moulder | Chairperson & CEO | Other Derivative Acquisition | +500,000 | $18.71 |
| 2026-06-14 | Patrick Gerald Enright | Director | Other Derivative Acquisition | +18,500 | $18.71 |
| 2026-06-14 | Jason Nunn | Director | Other Derivative Acquisition | +18,500 | $18.71 |
| 2026-06-14 | Jennifer Fox | Chief Business Officer & CFO | Other Derivative Acquisition | +125,000 | $18.71 |
| 2026-06-14 | Patricia L. Allen | Director | Other Derivative Acquisition | +18,500 | $18.71 |
| 2026-06-14 | Joseph Farmer | Chief Operating Officer | Other Derivative Acquisition | +175,000 | $18.71 |
| 2026-06-14 | John Orloff | Director | Other Derivative Acquisition | +18,500 | $18.71 |
| 2026-06-14 | Hongbo Lu | Director | Other Derivative Acquisition | +18,500 | $18.71 |
| 2026-06-14 | James Boylan | Director | Other Derivative Acquisition | +18,500 | $18.71 |
| 2026-06-14 | Lisa von Moltke | Head of Research & Development and Chief Medical Officer | Other Derivative Acquisition | +150,000 | $18.71 |
| 2026-05-17 | Leon Moulder | Chairperson & CEO | Open Market Acquisition | +60,000 | $16.88 |
| 2026-04-28 | Tellus BioVentures, LLC | -- | Open Market Acquisition | +60,000 | $17.62–18.02 |
| 2026-03-30 | Hongbo Lu | Director | Open Market Acquisition | +3,768 | $18.63 |
| 2026-03-30 | Fairmount Funds Management LLC | -- | Private Acquisition | +150,000 | $20.00 |
| 2026-03-30 | Tellus BioVentures, LLC | -- | Open Market Acquisition | +54,000 | $18.23–19.31 |
| 2026-03-30 | Nextbio Capital Management LP | -- | Private Acquisition | +75,000 | $20.00 |
| 2026-02-12 | Patricia L. Allen | Director | Open Market Acquisition | +19,860 | $23.77–26.50 |
| 2026-02-10 | Nextbio Capital Management LP | -- | Open Market Acquisition | +25,985 | $22.50 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:09:11 · For reference only, not investment advice and not tailored to your situation.